QLGN - Qualigen Therapeutics Inc
4.18
0.110 2.632%
Share volume: 15,298
Last Updated: Tue 21 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.36%
PREVIOUS CLOSE
CHG
CHG%
$4.07
0.11
0.03%
Fundamental analysis
6%
Profitability
0%
Dept financing
43%
Liquidity
13%
Performance
0%
Performance
5 Days
2.70%
1 Month
3.47%
3 Months
2,264.25%
6 Months
1,448.15%
1 Year
747.87%
2 Year
226.56%
Key data
Stock price
$4.18
DAY RANGE
$4.08 - $4.33
52 WEEK RANGE
$0.08 - $5.14
52 WEEK CHANGE
$752.19
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Michael S. Poirier
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.
Recent news